Published in Pediatr Infect Dis J on September 01, 1989
Varicella-zoster virus. Clin Microbiol Rev (1996) 3.03
"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev (1994) 1.54
Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr (2009) 1.11
Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin lesions. J Clin Microbiol (1995) 1.01
CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog (2011) 0.98
Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol (2010) 0.96
Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin Microbiol Rev (1995) 0.92
Intrabronchial infection of rhesus macaques with simian varicella virus results in a robust immune response in the lungs. J Virol (2014) 0.88
Pediatric human immunodeficiency virus infection. Clin Microbiol Rev (1996) 0.81
Herpes zoster and the search for an effective vaccine. Clin Exp Immunol (2016) 0.81
Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques. J Virol (2013) 0.77
Varicella-zoster virus infections: chronic disease in the immunocompromised host: evidence for persistent excretion of virus. Pediatr Infect Dis J (1989) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med (1991) 3.78
The effectiveness of the varicella vaccine in clinical practice. N Engl J Med (2001) 3.66
Failure of voluntary testing for human immunodeficiency virus to identify infected parturient women in a high-risk population. N Engl J Med (1988) 3.56
Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A (1998) 2.65
The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med (1991) 2.62
Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi network. J Virol (1995) 2.47
Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med (1995) 2.38
Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol (1992) 2.37
Antibody to Varicella-Zoster virus in parturient women and their offspring during the first year of life. Pediatrics (1976) 2.35
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med (1999) 2.33
The postmarketing safety profile of varicella vaccine. Vaccine (2000) 2.18
Group C beta-hemolytic streptococcal infections in children: nine pediatric cases and review. Rev Infect Dis (1989) 2.09
A gene cluster involved in the utilization of both free heme and heme:hemopexin by Haemophilus influenzae type b. J Bacteriol (1995) 2.08
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Congenital tuberculosis: critical reappraisal of clinical findings and diagnostic procedures. Pediatrics (1980) 2.01
Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol (1991) 1.89
Detection of antibody to Varicella-Zoster virus by immune adherence hemagglutination. Proc Soc Exp Biol Med (1976) 1.88
Cerebrospinal fluid endotoxin levels in children with H. influenzae meningitis before and after administration of intravenous ceftriaxone. J Infect Dis (1989) 1.87
Disclosing the diagnosis of HIV in pediatrics. J Clin Ethics (2001) 1.86
High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol (2000) 1.77
Cerebrospinal fluid cachectin/tumor necrosis factor-alpha and platelet-activating factor concentrations and severity of bacterial meningitis in children. J Infect Dis (1990) 1.74
Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol (2001) 1.72
Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics (1998) 1.69
Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA (1984) 1.65
Lymphocyte subsets in healthy children during the first 5 years of life. JAMA (1992) 1.64
Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation. J Virol (1989) 1.62
Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. Proc Natl Acad Sci U S A (1995) 1.60
Zoster immune globulin. A further assessment. N Engl J Med (1974) 1.57
Viral strain identification in varicella vaccinees with disseminated rashes. Pediatr Infect Dis J (2000) 1.56
Measles and measles immunity in children infected with human immunodeficiency virus. JAMA (1989) 1.56
Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. J Virol (2001) 1.55
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J (1990) 1.53
Erythrocyte adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme. J Clin Invest (1979) 1.50
Prospects for use of a varicella vaccine in adults. Infect Dis Clin North Am (1990) 1.48
Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster. J Infect Dis (1975) 1.47
Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate. J Pediatr (1999) 1.43
Cefuroxime treatment failure and Haemophilus influenzae meningitis: case report and review of literature. Pediatrics (1989) 1.43
In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b. Antimicrob Agents Chemother (1981) 1.40
A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol (1999) 1.38
Immunization of HIV-infected children with varicella vaccine. J Pediatr (2001) 1.35
Clinical reinfection with varicella-zoster virus. J Infect Dis (1984) 1.34
Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses (1998) 1.33
Fatal hepatitis B in early infancy: the importance of identifying HBsAg-positive pregnant women and providing immunoprophylaxis to their newborns. Pediatrics (1983) 1.33
Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics (1998) 1.32
Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis (1988) 1.28
Intrauterine infection with herpes simplex virus. Resultant congenital malformations. JAMA (1973) 1.28
Seroepidemiologic survey of varicella: Value of specific fluorescent antibody test. Pediatrics (1975) 1.27
Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol (2001) 1.26
Pneumocystis carinii pneumonia in infants infected with the human immunodeficiency virus with more than 450 CD4 T lymphocytes per cubic millimeter. N Engl J Med (1990) 1.25
Rapid enzyme-linked immunosorbent assay for detecting antibody to varicella-zoster virus. J Infect Dis (1988) 1.25
Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J Virol (1996) 1.24
Molecular cloning of a gene involved in lipooligosaccharide biosynthesis and virulence expression by Haemophilus influenzae type B. Mol Microbiol (1991) 1.24
Prognosis of human immunodeficiency virus infection in children and adolescents. Pediatr Infect Dis J (1989) 1.22
Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr (1985) 1.21
A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med (1991) 1.20
Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr (1994) 1.20
Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics (1998) 1.20
Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis (1990) 1.19
Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother (1999) 1.19
Peritonsillar abscess complicating infectious mononucleosis. J Pediatr (1984) 1.18
Tumors of smooth-muscle origin in HIV-infected children. JAMA (1990) 1.17
Prevention of varicella in high risk children: a collaborative study. Pediatrics (1972) 1.16
Passive immunization against varicella-zoster infections and other modes of therapy. J Infect Dis (1973) 1.15
Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med (2011) 1.14
Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr (1999) 1.14
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis (2001) 1.13
Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. Leuk Lymphoma (1997) 1.12
Antibiotic-induced bacterial killing stimulates tumor necrosis factor-alpha release in whole blood. J Infect Dis (1993) 1.12
Enzymatic amplification of the human immunodeficiency virus in peripheral blood mononuclear cells from pediatric patients. J Infect Dis (1989) 1.12
Effect of mutations in lipooligosaccharide biosynthesis genes on virulence of Haemophilus influenzae type b. Infect Immun (1990) 1.12
Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis. J Infect Dis (1986) 1.12
IgM to varicella-zoster virus: demonstration in patients with and without clinical zoster. Pediatr Infect Dis (1983) 1.11
Human-immunodeficiency-virus infections in infants negative for anti-HIV by enzyme-linked immunoassay. Lancet (1987) 1.11
The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med (1988) 1.11
Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS (1999) 1.11
Cholesterol dependence of varicella-zoster virion entry into target cells. J Virol (2007) 1.10